November 29, 2016 - By Adrian Mccoy
London: In an analyst note revealed to investors and clients on Tuesday, 29 November, N+1 Singer maintained their Buy rating on shares of Ergomed Plc (LON:ERGO). They currently have a GBX 275.00 price target on the firm. N+1 Singer’s target suggests a potential upside of 97.84% from the company’s stock close price.
Out of 3 analysts covering Ergomed (LON:ERGO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 290 is the highest target while GBX 265 is the lowest. The GBX 271 average target is 92.20% above today’s (GBX 141) stock price. Ergomed has been the topic of 15 analyst reports since September 29, 2015 according to StockzIntelligence Inc. The stock of Ergomed PLC (LON:ERGO) earned “Buy” rating by N+1 Singer on Wednesday, October 21. N+1 Singer maintained Ergomed PLC (LON:ERGO) on Friday, October 21 with “Buy” rating. On Tuesday, November 1 the stock rating was maintained by Stifel Nicolaus with “Buy”. As per Monday, September 26, the company rating was maintained by N+1 Singer. The rating was maintained by Stifel Nicolaus on Friday, September 2 with “Buy”. The stock has “Buy” rating given by Stifel Nicolaus on Thursday, September 22. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, October 21. Stifel Nicolaus maintained Ergomed PLC (LON:ERGO) rating on Monday, February 1. Stifel Nicolaus has “Buy” rating and GBX 281 price target. The firm has “Buy” rating given on Monday, November 7 by N+1 Singer. N+1 Singer maintained Ergomed PLC (LON:ERGO) on Wednesday, December 16 with “Buy” rating.
About 13,806 shares traded hands. Ergomed PLC (LON:ERGO) has declined 8.93% since April 28, 2016 and is downtrending. It has underperformed by 14.19% the S&P500.
Analysts await Entia Biosciences Inc (OTCMKTS:ERGO) to report earnings on December, 29.
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The company has a market cap of 56.01 million GBP. The Firm operates through two divisions: clinical research services , and drug safety and medical information services (DS&MI). It has a 31.24 P/E ratio. It provides a range of clinical trial planning, management and monitoring services.
According to Zacks Investment Research, “Entia Biosciences, Inc. is engaged in the discovery, scientific evaluation and marketing of natural formulations of medical foods, nutraceuticals, cosmetics and other products. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon.”
Entia Biosciences, Inc., incorporated on July 19, 2007, develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy